Table 2.

PD-L1 as a potential biomarker: % of PD-L1 positive patients in different clinical trials

Study	PDL1 positive patients (%)
CA209-037 [21]	49
CA209-066 [22]	35
Ca209-067 ipilimumab/nivolumab arm [7]	21.7
Ca209-067 nivolumab monotherapy arm [7]	25.3
Keynote 006 pembro every 2 weeks [23]	80.6
Keynote 006 pembro every 3 weeks [23]	79.8
Keynote 002 [24]	69
Keynote 001 [25]	77